Physician profile
Allen Danforth Pettee
NPI 1780671511
$6,325.75
in general payments reported to CMS, 2019-2025
45 companies · $126 in 2025
The $126 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,535 · 2020: $1,565 · 2021: $1,224 · 2022: $375 · 2023: $655 · 2024: $847 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,627.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $993.05 | 2021-2024 | |
| Genentech USA, INC. | $693.81 | 2019-2024 | Ocrevus |
| Supernus Pharmaceuticals, INC. | $604.12 | 2019-2025 | Qelbree |
| Novartis Pharmaceuticals Corporation | $552.36 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $546.55 | 2019-2022 | |
| Emd Serono, INC. | $498.00 | 2019-2024 | Mavenclad |
| Mdd US Operations, LLC | $234.01 | 2020-2025 | Gocovri, Apokyn |
| Sunovion Pharmaceuticals INC. | $219.58 | 2019-2020 | |
| Biogen, INC. | $179.70 | 2020-2022 | |
| Amgen INC. | $159.58 | 2020-2023 | Aimovig |
| Pfizer INC. | $142.08 | 2023-2025 | |
| Celgene Corporation | $141.53 | 2021-2023 | Zeposia |
| Lilly USA, LLC | $122.76 | 2020-2021 | |
| Upsher-Smith Laboratories LLC | $108.18 | 2020-2021 | |
| Genzyme Corporation | $99.56 | 2020-2021 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allen Pettee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.